Actively Recruiting
Phase 1 Study of Oral MOMA-341 Alone or with Irinotecan or Immunotherapy for Advanced or Metastatic Solid Tumors with MSI-H or dMMR
Led by MOMA Therapeutics · Updated on 2026-07-23
132
Participants Needed
15
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating MOMA-341, an oral investigational drug, in patients with advanced or metastatic solid tumors that have microsatellite instability high MSI-H or DNA mismatch repair deficiency dMMR. This Phase 1, multi-center, open-label study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical effects of MOMA-341 alone or in combination with chemotherapy or immunotherapy. The study focuses on patients who have progressed after prior anti-PD-L1 treatment or are ineligible for such therapies. Participants receive MOMA-341 administered orally either as a single agent in 21-day cycles, combined with irinotecan chemotherapy in 28-day cycles, or combined with immunotherapy in 21-day cycles. The study includes dose-escalation phases to find the optimal biologic dose and dose-optimization phases to confirm this dose. Data collected will support further development of MOMA-341 alone and in combination therapies. During the study, participants undergo safety monitoring including recording adverse events, dose-limiting toxicities, and serious side effects up to 35 months. Pharmacokinetic parameters like drug concentration and half-life are measured over approximately 6 weeks and beyond. Tumor response and progression outcomes are evaluated regularly. Participants provide informed consent and comply with contraceptive guidelines, and their overall health and organ functions are assessed throughout the trial.
CONDITIONS
Brief Title
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Research Team
M
MOMA Clinical Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here